Alexa Wnorowski

Alexa Wnorowski

Auto-generated profile, based on publicly available information

Alexa Wnorowski

Stanford University School of Medicine, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2019 in Circulation
Verified
Journal Article
Closed access
TSTimon Seeger
Timon Seeger
RSRajani Shrestha
Rajani Shrestha
Chi Keung LamChi Keung Lam
Chi Keung Lam
CCCaressa Chen
Caressa Chen
WMWesley L. McKeithan
Wesley L. McKeithan
JWJoseph C. Wu
Joseph C. Wu
Background: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 ( MYBPC3 ) resulting in a premature termination codon (PTC). The underlying mechanisms of how PTC mutations in MYBPC3 lead to the onset and progression of HCM are poorly understood. This study’s aim was to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations by utilizing human isogenic induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs). Methods: Isogenic iPSC lines were generated from HCM patients harboring MYBPC3 PTC mutations (p.R943x; p.R1073P_Fsx4) using genome editing. Comprehensive phenotypic and transcriptome analyses were performed in the iPSC-CMs. Results: We observed aberrant calcium handling properties with prolonged decay kinetics and elevated diastolic calcium levels in the absence of structural abnormalities or contracile dysfunction in HCM iPSC-CMs as compared to isogenic controls. The mRNA expression levels of MYBPC3 were significantly reduced in mutant iPSC-CMs, but the protein levels were comparable among isogenic iPSC-CMs, suggesting that haploinsufficiency of MYBPC3 does not contribute to the pathogenesis of HCM in vitro. Furthermore, truncated MYBPC3 peptides were not detected. At the molecular level, the nonsense-mediated decay pathway was activated, and a set of genes involved in major cardiac signaling pathways was dysregulated in HCM iPSC-CMs, indicating an HCM gene signature in vitro. Specific inhibition of the nonsense-mediated decay pathway in mutant iPSC-CMs resulted in reversal of the molecular phenotype and normalization of calcium-handling abnormalities. Conclusions: iPSC-CMs carrying MYBPC3 PTC mutations displayed aberrant calcium signaling and molecular dysregulations in the absence of significant haploinsufficiency of MYBPC3 protein. Here we provided the first evidence of the direct connection between the chronically activated nonsense-mediated decay pathway and HCM disease development.

1 February 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AWAlexa Wnorowski
Alexa Wnorowski
HYHuaxiao Yang
Huaxiao Yang
JWJoseph C. Wu
Joseph C. Wu

1 December 2019 in Stem Cell Reports
Verified
Journal Article
Open access
AWAlexa Wnorowski
Alexa Wnorowski
ASArun Sharma
Arun Sharma
HCHaodong Chen
Haodong Chen
HWHaodi Wu
Haodi Wu
NSNing-Yi Shao
Ning-Yi Shao
JWJoseph C. Wu
Joseph C. Wu
With extended stays aboard the International Space Station (ISS) becoming commonplace, there is a need to better understand the effects of microgravity on cardiac function. We utilized human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to study the effects of microgravity on cell-level cardiac function and gene expression. The hiPSC-CMs were cultured aboard the ISS for 5.5 weeks and their gene expression, structure, and functions were compared with ground control hiPSC-CMs. Exposure to microgravity on the ISS caused alterations in hiPSC-CM calcium handling. RNA-sequencing analysis demonstrated that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples, including genes involved in mitochondrial metabolism. This study represents the first use of hiPSC technology to model the effects of spaceflight on human cardiomyocyte structure and function.

29 July 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
NSNazish Sayed
Nazish Sayed
CLChun Liu
Chun Liu
MAMohamed Ameen
Mohamed Ameen
FHFarhan Himmati
Farhan Himmati
JZJoe Z. Zhang
Joe Z. Zhang
JWJoseph C. Wu
Joseph C. Wu
Patient-specific iPSCs model endothelial dysfunction in lamin A and C–related dilated cardiomyopathy and identify lovastatin as a therapy.

1 January 2017 in Integrative Biology
Verified
Journal Article
Closed access
PDF file
JDJackson G. DeStefano
Jackson G. DeStefano
AWAshley Williams
Ashley Williams
AWAlexa Wnorowski
Alexa Wnorowski
NYNahom Yimam
Nahom Yimam
PSPeter C. Searson
Peter C. Searson
AWAndrew D. Wong
Andrew D. Wong
Real-time quantification of endothelial cell morphology and activity under applied shear stress.

5 July 2019 in Circulation Research
Verified
Journal Article
Closed access
PDF file
Chi Keung LamChi Keung Lam
Chi Keung Lam
LTLei Tian
Lei Tian
NBNadjet Belbachir
Nadjet Belbachir
AWAlexa Wnorowski
Alexa Wnorowski
RSRajani Shrestha
Rajani Shrestha
JWJoseph C. Wu
Joseph C. Wu
Rationale:: Calcium channel blockers (CCBs) are an important class of drugs in managing cardiovascular diseases. Patients usually rely on these medications for the remainder of their lives after diagnosis. Although the acute pharmacological actions of CCBs in the hearts are well-defined, little is known about the drug-specific effects on human cardiomyocyte transcriptomes and physiological alterations after long-term exposure. Objective:: This study aimed to simulate chronic CCB treatment and to examine both the functional and transcriptomic changes in human cardiomyocytes. Methods and Results:: We differentiated cardiomyocytes and generated engineered heart tissues from 3 human induced pluripotent stem cell lines and exposed them to 4 different CCBs—nifedipine, amlodipine, diltiazem, and verapamil—at their physiological serum concentrations for 2 weeks. Without inducing cell death and damage to myofilament structure, CCBs elicited line-specific inhibition on calcium kinetics and contractility. While all 4 CCBs exerted similar inhibition on calcium kinetics, verapamil applied the strongest inhibition on cardiomyocyte contractile function. By profiling cardiomyocyte transcriptome after CCB treatment, we identified little overlap in their transcriptome signatures. Verapamil is the only inhibitor that reduced the expression of contraction-related genes, such as MYH (myosin heavy chain) and troponin I, consistent with its depressive effects on contractile function. The reduction of these contraction-related genes may also explain the responsiveness of patients with hypertrophic cardiomyopathy to verapamil in managing left ventricular outflow tract obstruction. Conclusions:: This is the first study to identify the transcriptome signatures of different CCBs in human cardiomyocytes. The distinct gene expression patterns suggest that although the 4 inhibitors act on the same target, they may have distinct effects on normal cardiac cell physiology.